drugset / Trial / NCT00536484
Fesoterodine Flexible Dose Study
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This Phase 3B study is designed to test if a fesoterodine flexible dose regimen is more effective than placebo in reducing micturition frequency and other overactive bladder (OAB) symptoms, e.g., urgency, urgency incontinence episodes in patients with overactive bladder and if the fesoterodine regimen is safe and well tolerated.
Timeline
- Start
- 2007-08
- Primary completion
- 2008-03
- Completion
- 2008-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fesoterodine | Other / unclassified | 4 mg | Oral |
| Subject | Fesoterodine | Other / unclassified | 8 mg | Oral |